Edwin Ho

ORCID: 0000-0003-1889-4869
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiac Valve Diseases and Treatments
  • Infective Endocarditis Diagnosis and Management
  • Cardiovascular Function and Risk Factors
  • Cardiac Imaging and Diagnostics
  • Cardiac Structural Anomalies and Repair
  • Aortic Disease and Treatment Approaches
  • Cardiac Arrhythmias and Treatments
  • Cardiac pacing and defibrillation studies
  • Pulmonary Hypertension Research and Treatments
  • Cardiac, Anesthesia and Surgical Outcomes
  • Mechanical Circulatory Support Devices
  • Cardiovascular Issues in Pregnancy
  • Ultrasound in Clinical Applications
  • COVID-19 and healthcare impacts
  • Coronary Interventions and Diagnostics
  • Transplantation: Methods and Outcomes
  • Cardiac Arrest and Resuscitation
  • Acute Myocardial Infarction Research
  • T-cell and B-cell Immunology
  • Congenital Heart Disease Studies
  • Cardiomyopathy and Myosin Studies
  • Heart Failure Treatment and Management
  • Cardiac electrophysiology and arrhythmias
  • Immune Cell Function and Interaction
  • Diabetes Treatment and Management

Montefiore Medical Center
2019-2025

Albert Einstein College of Medicine
2020-2024

The University of Sydney
2011-2023

The Bronx Defenders
2023

Lankenau Medical Center
2023

St. Michael's Hospital
2016-2021

University of Toronto
2016-2021

Laboratoire des Sciences de l'Ingénieur, de l'Informatique et de l'Imagerie
2021

University Hospital of Zurich
2018-2020

University of Zurich
2018-2020

Abstract High expression of CXCR5 is one the defining hallmarks T follicular helper cells (TFH), a CD4 Th cell subset that promotes germinal center reactions and selection affinity maturation B cells. also expressed on 20–25% peripheral blood human central memory (TCM), although definitive function these not fully understood. The constitutive TFH fraction circulating TCM suggests CXCR5+ may represent specialized memory-type programmed for homing to follicles providing help. To verify this...

10.4049/jimmunol.1002828 article EN The Journal of Immunology 2011-04-07
Susheel Kodali Rebecca T. Hahn Raj Makkar Moody Makar Charles J. Davidson and 95 more Jyothy Puthumana Firas Zahr Scott Chadderdon Neil Fam Géraldine Ong Pradeep Yadav Vinod H. Thourani Mani A. Vannan William W. O’Neill Dee Dee Wang Didier Tchetchè Nicolas Dumonteil Laurent Bonfils Laurent Lepage Robert L. Smith Paul Grayburn Rahul Sharma Christiane Haeffele Vasilis Babaliaros Patrick Gleason Sammy Elmariah Ignacio Inglessis‐Azuaje Jonathan Passeri Howard C. Herrmann Frank E. Silvestry Scott Lim Dale Fowler John G. Webb Robert Moss Thomas Modine Stéphane Lafitte Azeem Latib Edwin Ho Ythan Goldberg Pinak Shah Charles Nyman Josep Rodés‐Cabau Élisabeth Bédard Nicolas Brugger Anna Sannino Michael J. Mack Martin B. Leon Stephan Windecker Raj Makkar Tarun Chakravarty Jubin Joseph Mamoo Nakamura Luke Oakley Wen Cheng Moody Makar Siddharth Singh John D. Friedman D. Chang Michèle A. Hamilton Siddharth Singh Charles J. Davidson Laura Davidson Duc Thinh Pham S. Chris Malaisrie Jyothy Puthumana Akhil Narang Ryan Avery Kambiz Ghafourian Firas Zahr Howard K. Song Scott Chadderdon Christina Fuss Johannes Steiner Susheel Kodali Vivian G. Ng Torsten Vahl Isaac George Rebecca T. Hahn Omar Khalique Todd Pulerwitz Amirali Masoumi Neil Fam Sami Alnasser Mark D. Peterson Gianluigi Bisleri Géraldine Ong Djeven P. Deva Gordon W. Moe Pradeep Yadav Vivek Rajagopal Vinod H. Thourani James Kauten Mani A. Vannan Sara Mobasseri Hassan Sayegh William Dinsfriend Vibhav Rangarajan Raul R. Blanco Peter Flueckiger Roshin C. Mathew

For patients with symptomatic, severe tricuspid regurgitation (TR), early results of transcatheter valve (TV) intervention studies have shown significant improvements in functional status and quality life associated right-heart reverse remodelling. Longer-term follow-up is needed to confirm sustained these outcomes.

10.1093/eurheartj/ehad667 article EN European Heart Journal 2023-11-01

Tricuspid regurgitation (TR) has a poor prognosis and limited treatment options is frequently accompanied by right ventricular (RV) dysfunction. Transcatheter tricuspid valve interventions (TTVI) to reduce TR have been shown be safe feasible with encouraging early results. Patient selection for TTVI remains challenging, the role of function being unknown.The aims this study were 1) investigate survival in TTVI-treated patient population conservatively treated population, 2) evaluate outcome...

10.4244/eij-d-21-00191 article EN EuroIntervention 2021-07-01

Analysis of females carriers the X-linked lymphoproliferative (XLP) trait reveals mechanism underlying exquisite sensitivity XLP patients to often-fatal infection with normally innocuous Epstein-Barr virus.

10.1371/journal.pbio.1001187 article EN cc-by PLoS Biology 2011-11-01

Abstract Objectives We investigated the durability of tricuspid regurgitation (TR) reduction and clinical outcomes through 12 months after transcatheter valve repair (TTVr) with PASCAL Transcatheter Valve Repair System. Background TTVr has rapidly developed demonstrated favorable acute outcomes, but longer follow‐up data are needed. Methods Overall, 30 patients (age 77 ± 6 years; 57% female) received implantation from September 2017 to May 2019 completed a at months. Results The TR etiology...

10.1002/ccd.29583 article EN cc-by-nc Catheterization and Cardiovascular Interventions 2021-03-04
Coming Soon ...